Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00337415
First received: June 14, 2006
Last updated: October 8, 2014
Last verified: October 2014
  Purpose

A Research Study to Evaluate the Effectiveness and Tolerability of MK0354 vs Placebo (an inactive look alike pill) in Lipid (fat) Altering in Patients with dyslipidemia (a disorder of lipids in the blood)

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Dyslipidemia
Drug: MK0354
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Proprietary Information - Exploratory (Non-Confirmatory) Trial

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • proprietary information - exploratory (non-confirmatory) trial

Secondary Outcome Measures:
  • proprietary information - exploratory (non-confirmatory) trial

Enrollment: 65
Study Start Date: May 2006
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is between 18 and 75 years of age
  • You have taken a statin or other lipid modifying therapy in the last 6-8 weeks
  • You have lipid lab values outside of the range specified in the protocol

Exclusion Criteria:

  • Patient is a woman who is pregnant or nursing a child
  • Patient is a woman who is taking hormonal birth-control
  • You are a woman who is planning to donate eggs during the study
  • You plan to give blood during the study or have given within the last 8 weeks
  • You are a woman who is having menopausal hot flashes or are taking medications to prevent menopausal hot flashes
  • You have a known intolerance to or you are allergic to niacin
  • You have any of the following medical conditions:
  • Poorly controlled or newly diagnosed diabetes (within the last 3 months)
  • Thyroid disease (hypothyroidism or hyperthyroidism)
  • A history of stroke, heart attack, coronary bypass surgery, angioplasty, unstable angina or similar heart and artery procedures in the past 3 months
  • History of hemorrhagic stroke or other non-traumatic hemorrhage
  • Peptic ulcer disease in the last 3 months
  • An occurrence of gout within the last year and you are not currently taking allopurinol
  • Cancer (except for successfully treated skin cancer)
  • HIV positive
  • You have a history of drug/alcohol abuse within the last year
  • You consume more than 2 drinks of alcohol per day
  • You do not have access to a telephone
  • You take medications that are not allowed in this study. The study doctor or staff will discuss this with you.
  • Patient has participated in a study with an investigational drug within the last 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00337415

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00337415     History of Changes
Other Study ID Numbers: 0354-004
Study First Received: June 14, 2006
Last Updated: October 8, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on November 20, 2014